Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mesalamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 2/20 | 0.96 |
| ▸ | ALOX5 known ✓ | P09917 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.96 |
| ▸ | HPGD | P15428 | 3/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.96 |
| ▸ | THRB | P10828 | 2/20 | 0.96 |
| ▸ | RECQL | P46063 | 2/20 | 0.96 |
| ▸ | KDR | P35968 | 2/20 | 0.96 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.96 |
| ▸ | TNF | P01375 | 1/20 | 0.96 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.96 |
| ▸ | CASP1 | P29466 | 1/20 | 0.96 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mesalamine SCHEMBL1967328 | 0.98 | KDM4E (1.00) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| Mesalamine SCHEMBL28077836 | 0.98 | KDM4E (1.00) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| Mesalamine SCHEMBL31297 | 0.98 | KDM4E (1.00) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| Mesalamine SCHEMBL29354798 | 0.98 | KDM4E (1.00) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| Mesalamine SCHEMBL10493008 | 0.96 | KDM4E (0.96) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| Mesalamine SCHEMBL15329203 | 0.96 | KDM4E (0.96) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| Mesalamine SCHEMBL2680203 | 0.96 | KDM4E (0.96) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| Mesalamine SCHEMBL9688231 | 0.96 | KDM4E (0.96) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| Mesalamine SCHEMBL2679950 | 0.96 | KDM4E (0.96) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| Mesalamine SCHEMBL2680533 | 0.96 | KDM4E (0.96) | MEN1KMT2AKDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3044203-B1 | PROCESS FOR THE PRODUCTION OF HIGH-DENSITY MESALAMINE | ERREGIERRE SPA (IT) | 2018-09-05 | — | — | EP | claimed |
| EP-3044203-A1 | PROCESS FOR THE PRODUCTION OF HIGH-DENSITY MESALAMINE | ERREGIERRE S.p.A. (IT) | 2016-07-20 | — | — | EP | claimed |
| WO-2015036920-A1 | PROCESS FOR THE PRODUCTION OF HIGH-DENSITY MESALAMINE | ERREGIERRE S.P.A. (IT) | 2015-03-19 | — | — | WO | claimed |
| WO-2012090224-A1 | NOVEL COCRYSTALS / MOLECULAR SALTS OF MESALAMINE TO BE USED AS IMPROVED ANTI-INFLAMMATORY DRUG | NUTRACRYST THERAPEUTICS PRIVATE LIMITED (IN) | 2012-07-05 | — | — | WO | claimed |
| JP-2023890-A | — | — | None | — | — | JP | disclosed |
| CN-118239854-A | Mesalamine-palmatine hydrochloride pharmaceutical co-crystal and preparation method and application thereof | 福州大学 | 2024-06-25 | — | — | CN | disclosed |
| CN-118184529-A | Preparation method of low-chloride mesalazine | 浙江恒康药业股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-118184529-A | Preparation method of low-chloride mesalazine | 浙江恒康药业股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-112272557-B | System for moulding and coating pharmaceutical tablets | 康蒂纽斯制药公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-111662281-B | Salicylic acid berberine type alkaloid quaternary ammonium salt and application thereof in preparing medicines | 中国医学科学院药物研究所 | 2023-01-06 | — | — | CN | disclosed |
| CN-111662281-A | Salicylic acid berberine type alkaloid quaternary ammonium salt and application thereof in preparing medicines | 中国医学科学院药物研究所 | 2020-09-15 | — | — | CN | disclosed |
| US-20180263940-A1 | TREATMENT OF SKIN CONDITIONS | MONASH UNIVERSITY (AU) | 2018-09-20 | — | — | US | disclosed |
| US-4650753-A | Novel substrates for use in measuring the concentration of kallikrein in urine | NITTO BOSEKI CO., LTD. (JP) | 1987-03-17 | — | — | US | disclosed |
| US-4622389-A | Novel substrate for determining the activity of blood coagulation factor Xa (Stuart-Prower factor) | Nitto Poseki Co., Ltd. (JP) | 1986-11-11 | — | — | US | disclosed |
| EP-0170797-A1 | Novel substrate for determining the activity of blood coagulation factor Xa (Stuart-Prower Factor) | NITTO BOSEKI CO., LTD. (JP) | 1986-02-12 | — | — | EP | disclosed |
| EP-0167980-A2 | Novel substrates for use in measuring the concentration of kallikrein in urine | NITTO BOSEKI CO., LTD. (JP) | 1986-01-15 | — | — | EP | disclosed |
| EP-0094789-B1 | NOVEL METHOD FOR DETERMINATION OF 5-AMINOSALICYLIC ACID | NITTO BOSEKI CO., LTD. (JP) | 1985-08-28 | — | — | EP | disclosed |
| US-4529709-A | Colorimetric analysis using o-alkylphenol and a 5-aminosalicylic acid | NITTO BOSEKI CO. LTD. (JP) | 1985-07-16 | — | — | US | disclosed |
| EP-0094789-A1 | Novel method for determination of 5-aminosalicylic acid | NITTO BOSEKI CO., LTD. (JP) | 1983-11-23 | — | — | EP | disclosed |
| JP-H00223890-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180263940-A1 | TREATMENT OF SKIN CONDITIONS | ASAH2, ASAH1, ACER2 | PTGS2 689/4885ALOX5 41/4885MEN1 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.